The mutating SARS-CoV-2 is gaining virulence against the young COVID-19 patients | Demiurge Technologies

“As the world’s first AI-biopharma company that has discovered and publicized the precise aetiology and pathology of COVID-19, we are committed to the non-profit dissemination of our COVID-19 discoveries and the public validation of our COVID-19 clinical predictions.”

Read the full article @ Demiurge Technologies:

The Mutating SARS-CoV-2 Is Gaining Virulence Against the Young COVID-19 Patients
SWITZERLAND, THURSDAY, 7 MAY 2020 10:00 PM CET As the world’s first AI-biopharma company that has discovered and publicized the precise aetiology and pathology of COVID-191, we are

3,690 thoughts on “The mutating SARS-CoV-2 is gaining virulence against the young COVID-19 patients | Demiurge Technologies”

  1084. Hallo Nice blog! Is your theme custom made or did you download it from somewhere? A design like yours with a few simple tweeks would really make my blog stand out. thank you

    Reply

  1495. This membrane normally has a low permeability to sodium, and there is no reason to expect that the permeability for lithium is appreciably different in lithium treated individuals 6 Priligy

    Reply

  1574. When Kevin was a little bit dumbfounded, at the corner of the street, a few figures he was very familiar with While Taking priligy amazon GLUMETZA is contraindicated in patients with an estimated glomerular filtration rate eGFR below 30 mL minute 1

    Reply